✦ LIBER ✦

Oral butyrate for mildly to moderately active Crohn's disease

✍ Scribed by A. DI SABATINO; R. MORERA; R. CICCOCIOPPO; P. CAZZOLA; S. GOTTI; F. P. TINOZZI; S. TINOZZI; G. R. CORAZZA

Book ID: 108604247
Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 86 KB
Volume: 22
Category: Article
ISSN: 0269-2813
DOI: 10.1111/j.1365-2036.2005.02639.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Use of 6-mercaptopurine/azathioprine as

Use of 6-mercaptopurine/azathioprine as the immunomodulator of choice for moderately active Crohn's disease. Pro

✍ Jeffrey S. Hyams 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 47 KB

Use of 6-mercapturine/azathioprine as th

Use of 6-mercapturine/azathioprine as the immunomodulator of choice for moderately active Crohn's disease. Con

✍ Anne M. Griffiths 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 47 KB

Use of 6-mercaptopurine/azathioprine as

Use of 6-mercaptopurine/azathioprine as the immunomodulator of choice for moderately active Crohn's disease. Balance

✍ Douglas A. Jacobstein; Robert N. Baldassano 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 47 KB

A phase 1/2A Trial of STA 5326, an oral

A phase 1/2A Trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease

✍ Robert Burakoff; Charles F. Barish; Dennis Riff; Ronald Pruitt; William Y. Chey; 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 258 KB

Medical management of mild to moderate C

Medical management of mild to moderate Crohn’s disease: evidence-based treatment algorithms for induction and maintenance of remission

✍ W. J. SANDBORN; B. G. FEAGAN; G. R. LICHTENSTEIN 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 660 KB

Randomized, double-blind, placebo-contro

Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease

✍ Bruce E. Sands; Eric W. Jacobson; Thomas Sylwestrowicz; Ziad Younes; Gerald Dryd 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 349 KB 👁 1 views

## Background: Interleukin-12 (il-12) and interleukin-23 (il-23) are inflammatory cytokines linked to the th-1 and th-17 phenotypes associated with crohn's disease (cd). we investigated the activity and safety of apilimod mesylate (formerly sta-5326), an oral il-12 and il-23 inhibitor, in patients